Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France. The company has 45 total employees and is listed on Euronext Growth Paris.
The company focuses exclusively on intracellular DNA-binding targets and designs and develops first-in-class treatments for oncology and inflammatory diseases precision therapeutics from preclinical research to human clinical proof-of-concept studies. The company's portfolio is based on platON™, Valerio Therapeutics' decoy oligonucleotide platform, and the V-body platform, a bispecific T-cell engagers, antibody drug conjugates, and chimeric antigen receptors.
In 2026, Valerio launched InVimmune, a new subsidiary for in vivo cell therapy, appointed Gilles Besin as Chief Executive Officer, and signed a definitive agreement to acquire Etherna Immunotherapies NV to consolidate complementary technologies.
Facts compiled by Executive Moves from publicly available news and press releases on 9 October 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the Valerio Therapeutics team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
